Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) COO Anish Patel sold 716 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total value of $21,480.00. Following the completion of the transaction, the chief operating officer now owns 343,311 shares of the company’s stock, valued at $10,299,330. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Enliven Therapeutics Stock Down 0.0 %
NASDAQ:ELVN opened at $28.97 on Thursday. The company has a market cap of $1.36 billion, a P/E ratio of -15.01 and a beta of 1.10. The firm’s 50 day moving average is $24.52 and its two-hundred day moving average is $22.88. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $30.03.
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. Research analysts forecast that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.
Institutional Trading of Enliven Therapeutics
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.
Check Out Our Latest Analysis on Enliven Therapeutics
Enliven Therapeutics Company Profile
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- What is the S&P 500 and How It is Distinct from Other Indexes
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What Are Dividends? Buy the Best Dividend Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Do ETFs Pay Dividends? What You Need to Know
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.